ALMS today
$6.13-$0.49 (-7.40%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $7.31
Key levels
Resistance$6.75
Resistance$6.21
Support$5.75
Support$4.88
Latest news & SEC filings
SEC FilingAlumis Inc. filed a report on a major company event (Form 8-K)
EarningsAlumis Inc. to report Q3 2026 financial results
All ALMS news →About Alumis
Alumis is a drug developer focused on targeted treatments for immune system disorders. Its main candidate, envudeucitinib, is an allosteric TYK2 inhibitor being tested in late-stage trials for plaque psoriasis and in mid-stage testing for lupus. A second TYK2 inhibitor, A-005, is intended to act within the central nervous system for neuroinflammatory conditions. The company also picked up lonigutamab, an antibody candidate for thyroid eye disease.
Based on the company's 10-K filed Mar 19, 2026.
Nasdaq · Healthcare
ALUMIS INC. (ALMS)
What Is the Price Target for ALMS?
SEPT Low Target
$15.00
SEPT Mid Target
$31.50
SEPT High Target
$40.00
Analyst Consensus
$31.50
Is ALMS a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ALMS.
Start Free Trial →Is ALMS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$25.90
10
Moat Score
NONE
2/9
Piotroski Score
-3.0
Altman Z-Score
What Is Smart Money Doing with ALMS?
Insider Signal
NEUTRAL
3 buys / 2 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Drappa Jorn | officer | Sale | 593 | $4K | Nov 2, 2026 |
| Schroer John R. | officer | Sale | 794 | $5K | Nov 2, 2026 |
| Hardiman Roy C. | officer | Sale | 652 | $4K | Nov 2, 2026 |
| Goldstein David M | officer | Sale | 629 | $4K | Nov 2, 2026 |
| Pangali Sanam | officer | Sale | 332 | $2K | Nov 2, 2026 |
| Bradley Mark Christopher | officer | Sale | 623 | $4K | Nov 2, 2026 |
| AKKARAJU SRINIVAS | director | Sale | 48,066 | $507K | Sep 8, 2026 |
| AKKARAJU SRINIVAS | director | Sale | 48,065 | $507K | Sep 8, 2026 |
| AKKARAJU SRINIVAS | director | Buy | 273,291 | $2.9M | Sep 8, 2026 |
| AKKARAJU SRINIVAS | director | Buy | 273,290 | $2.9M | Sep 8, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ALMS Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
72.45%
FCF Growth YoY
-44.1%
Revenue Trend
UNKNOWN
Dark Pool Trades for ALMS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ALMS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:30:06 | $6.13 | 1,000 | $$6K | SELL |
| 21:00:06 | $6.13 | 1,292 | $$8K | SELL |
| 21:00:06 | $6.13 | 17,746 | $$109K | SELL |
| 21:00:06 | $6.13 | 1,558 | $$10K | SELL |
| 21:00:06 | $6.13 | 1,157 | $$7K | SELL |
5 dark pool trades shown · $$139K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ALUMIS INC. (ALMS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ALMS — frequently asked questions
What is ALMS stock price today?
ALUMIS INC. (ALMS) is at $6.13, down 7.40% (-$0.49) at the Nov 12, 2026 close.
Why is ALMS stock moving today?
Latest ALMS news — Nov 12, 2026: Alumis Inc. filed a report on a major company event (Form 8-K) · Nov 5, 2026: Alumis Inc. to report Q3 2026 financial results
What is the ALMS price target?
The average analyst price target for ALMS is $31.50, ranging from $15 to $40, based on 6 analysts. Latest: Wells Fargo maintains on Sep 2, 2026.
What do analysts rate ALMS?
Analyst ratings for ALMS: 1 Buy, 9 Hold, 1 Sell — consensus Hold.
Did ALMS beat earnings?
ALMS last reported on Aug 13, 2026: EPS -$1.11 vs -$0.77 expected — a miss of 44.7%.
Does ALMS pay a dividend?
ALMS does not currently pay a dividend.
What are ALMS support and resistance levels?
Support: $5.75, $4.88, $4.38. Resistance: $6.21, $6.75, $7.25.
What are insiders doing with ALMS?
Insider activity: NEUTRAL, 3 buys and 2 sells in the last 90 days.
What is the latest news on ALMS?
Nov 12, 2026: Alumis Inc. filed a report on a major company event (Form 8-K) · Nov 5, 2026: Alumis Inc. to report Q3 2026 financial results